Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma
Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.
Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.
Data from the phase II FIGHT-202 trial were presented at the 2019 ESMO Congress and demonstrated durable objective responses to treatment with pemigatinib in more than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion. Currently, there is no well established second-line therapy, says Vogel.
The objective response rate (ORR) among patients with FGFR2 fusions/rearrangements was 35.5%, and the median duration of response was 7.5 months. Notably, complete responses were seen in addition to partial responses, says Vogel. Notably, the higher ORR was associated with a longer median progression-free survival in patients with FGFR2 fusions/rearrangements.
Overall survival (OS) data were immature at the time of analysis, but with a median duration of follow-up of 15.4 months and a median duration of treatment of 7.2 months, the median OS was 21.1 months in the cohort with FGFR2 fusions/rearrangements.
